Biotech Values

[DewDiligence]

…why would [MNTA’s] lawsuit cause Marth to admit the application may get something other than approval.

MNTA and NVS believe that the only way Teva could get FDA approval for Lovenox is by stealing or infringing MNTA’s IP. Now that the patent-infringement lawsuit has been served on Teva, the kinds of assertions about Lovenox that we’ve come to expect from Bill Marth could conceivably be used against Teva in court. This has had the effect of gagging Marth’s urge to spout BS in presentations to investors.